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ABSTRACT
Background
The DOTS (directly observed treatment short-course) strategy for tuberculosis (TB) control is
recommended by the World Health Organization globally. However, there are few studies of
long-term TB treatment outcomes from DOTS programs in high-burden settings and
particularly settings of high drug resistance. A DOTS program was implemented progressively
in Karakalpakstan, Uzbekistan starting in 1998. The total case notification rate in 2003 was 462/
100,000, and a drug resistance survey found multidrug-resistant (MDR) Mycobacterium
tuberculosis strains among 13% of new and 40% of previously treated patients. A retrospective,
observational study was conducted to assess the capacity of standardized short-course
chemotherapy to effectively cure patients with TB in this setting.
Methods and Findings
Using routine data sources, 213 patients who were sputum smear-positive for TB, included in
the drug resistance survey and diagnosed consecutively in 2001–2002 from four districts, were
followed up to a median of 22 months from diagnosis, to determine mortality and subsequent
TB rediagnosis. Valid follow-up data were obtained for 197 (92%) of these patients. Mortality
was high, with an average of 15% (95% confidence interval, 11% to 19%) dying per year after
diagnosis (6% of 73 pansusceptible cases and 43% of 55 MDR TB cases also died per year).
While 73 (74%) of the 99 new cases were ‘‘successfully’’ treated, 25 (34%) of these patients
were subsequently rediagnosed with recurrent TB (13 were smear-positive on rediagnosis).
Recurrence ranged from ten (23%) of 43 new, pansusceptible cases to six (60%) of ten
previously treated MDR TB cases. MDR M. tuberculosis infection and previous TB treatment
predicted unsuccessful DOTS treatment, while initial drug resistance contributed substantially
to both mortality and disease recurrence after successful DOTS treatment.
Conclusions
These results suggest that specific treatment of drug-resistant TB is needed in similar settings
of high drug resistance. High disease recurrence after successful treatment, even for drug-
susceptible cases, suggests that at least in this setting, end-of-treatment outcomes may not
reflect the longer-term status of patients, with consequent negative impacts for patients and
for TB control.
The Editors’ Summary of this article follows the references.
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Tuberculosis (TB) has arguably killed more human beings
than any other disease throughout history. Into the 21st
century it is still one of the leading infectious causes of death,
killing at least 2 million people every year [1,2]. In 1993, the
World Health Organization (WHO) declared TB a global
emergency and subsequently launched the DOTS (directly
observed treatment short-course) strategy to control TB. The
aim of DOTS was to detect and treat cases of sputum smear-
positive TB in order to reduce further transmission and
control the spread of the disease.
DOTS is a management strategy consisting of ﬁve
principles: government commitment, passive case detection
based on sputum smear microscopy, DOTS chemotherapy
treatment regimens, an uninterrupted drug supply, and a
standardized recording and reporting system. DOTS is now
the internationally accepted strategy for controlling TB, with
183 countries implementing it and 4.4 million DOTS cases
reported in 2004 [2]. For control of TB, DOTS programs aim
to detect 70% of incident cases and to successfully treat 85%
of these. Treatment success is based on end-of-treatment
outcomes [3], and as there is no standardized system of
monitoring patients after treatment to conﬁrm cure or
record recurrent TB, published data are scant on rates of
recurrence from routine DOTS programs, particularly in
settings of high drug resistance.
Several studies suggest that patients infected with drug-
resistant strains of Mycobacterium tuberculosis do poorly when
placed on standard short-course chemotherapy. End-of-
treatment outcomes in patients infected with multidrug-
resistant (MDR) TB, deﬁned as resistance to at least isoniazid
and rifampicin, are reported to be no better than in the
prechemotherapy era [4–7]. However, data are more limited
on the impact of initial drug resistance on rates of relapse
following cure. High recurrence, which can be either relapse
of the same infection or reinfection, has been reported
among small numbers of successfully treated patients
diagnosed with MDR TB or with rifampicin-resistant TB [8–
12]. These data suggest that in high drug-resistance settings,
end-of-treatment outcomes may not represent cure and
therefore may exaggerate the potential impact of DOTS on
TB control. This retrospective, observational study aimed to
assess recurrent TB and mortality following treatment in such
a setting.
Methods
Setting
The Autonomous Republic of Karakalpakstan in Uzbeki-
stan has a high TB burden (total case notiﬁcations 462/
100,000/year) and high drug resistance (13% among new and
40% among previously treated patients) [13]. The DOTS
strategy was implemented progressively in this region starting
in 1998, in line with recommendations from WHO [3] and the
International Union Against Tuberculosis and Lung Disease
(IUATLD) [14], replacing the existing Soviet-style system of
TB diagnosis and treatment. In 2003 it covered the total
population of approximately 1.5 million. Support for DOTS
implementation from Me ´decins Sans Frontie `res (MSF, Doc-
tors without Borders) included infrastructural support for
inpatient facilities and laboratories, extensive training and
supervision, drug supply, and overall program monitoring.
Treatment success for new smear-positive patients registered
in 2002 was 74%.
Study Design
A retrospective observational study of a cross-sectional
sample of sputum smear-positive TB patients was used to
determine the association between DOTS end-of-treatment
outcomes, subsequent rediagnosis of active TB, death, and
other predictors, including drug resistance.
Definitions
DOTS treatment outcomes were deﬁned according to
WHO recommendations [3]; ‘‘cure’’ was deﬁned as a negative
sputum smear at the end of treatment and on one previous
occasion among patients initially sputum smear-positive.
Patients who completed treatment without conﬁrmation of
cure through sputum smear and without evidence of treat-
ment failure were termed ‘‘treatment complete’’. Treatment
success includes these two categories. The term TB recur-
rence is used throughout this study to denote a recorded
rediagnosis of TB (either sputum smear-positive or -negative)
after ‘‘successful’’ DOTS TB treatment. Recurrence rather
than relapse is used, because the lack of DNA ﬁngerprinting
data at rediagnosis made it impossible to determine whether
recurrences were due to relapse of the same infection or
reinfection with a new strain. Smear-negative recurrence was
the term used when a patient with a negative smear
microscopy result was started on the DOTS retreatment
regimen. This decision was made routinely in the program
only after review of the patient ﬁle by a treatment committee,
which included MSF clinicians. Death was recorded for a
patient who died for any reason either during treatment or
subsequently.
Terms used to describe resistance in the causative M.
tuberculosis strains are: monoresistant, resistant to one ﬁrst-
line drug; polyresistant, resistant to more than one ﬁrst-line
drug, but not MDR; MDR, resistant to at least rifampicin and
isoniazid; and pansusceptible, susceptible to all ﬁve ﬁrst-line
drugs.
Study Population
The study population included all patients, recruited as
previously described [13] for a cross-sectional survey of drug
resistance. Brieﬂy, all patients from four districts in Kar-
akalpakstan, diagnosed as sputum smear-positive within the
DOTS program between July 2001 and January 2002, were
sequentially requested to participate. Overall, 68% of eligible
patients were recruited. The main reasons for nonrecruit-
ment were refusal to participate (due to initial poor
communication), patient default before sputum collection
for drug susceptibility testing (DST), and logistic constraints
in the timely collection and transport of sputum samples. The
nonparticipants were not signiﬁcantly different in terms of
age, sex, or district, and the ﬁnal sample was considered
representative of TB patients diagnosed and treated under
the DOTS strategy in Karakalpakstan.
Written informed consent was obtained from patients
prior to inclusion in the initial drug resistance survey, and the
observational study was approved by the University of
Melbourne Human Research Ethics Committee, the MSF
International Ethical Review Board, and the Ethical commit-
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Further individual patient consent was not obtained for the
retrospective observational study.
DOTS TB Treatment
Patients were treated, irrespective of drug resistance, using
one of two standard regimens [3]. The WHO category 1
regimen, for new patients, consisted of 2 mo of daily
isoniazid, rifampicin, pyrazinamide, and ethambutol (with
or without streptomycin) followed by 4 mo of isoniazid and
rifampicin, three times weekly. The category 2 regimen, for
previously treated patients, consisted of all ﬁve drugs daily for
3 mo minus streptomycin for the last month, followed by 5
mo of isoniazid, rifampicin, and ethambutol three times
weekly. All patients were hospitalized during the intensive
phase of treatment and received doses in the continuation
phase ostensibly under direct observation by health care
workers.
Data Sources
Patients were retrospectively tracked through two data
sources. The ﬁrst was the DOTS database, a computerized
database containing registration, treatment progress, and
outcome data for all patients registered in Karakalpakstan.
The data contained in the database is entered centrally from
the paper-based registration books maintained in each
district. The registration and recording system is based on
that recommended by the IUATLD [14].
Second, patients were tracked through a paper-based TB
patient record system (ambulatory cards), independent from
DOTS and continued from the pre-DOTS TB treatment
system. This system was continued because DOTS was not, at
the time, the national TB strategy for Uzbekistan, and
therefore national-level reporting was still required under
the old system of patient classiﬁcation and outcome
deﬁnition [15]. Patients were therefore seen regularly as
outpatients after DOTS treatment, regardless of clinical
status, for long periods of time, sometimes up to many years,
with the ambulatory cards updated regularly.
Death data were obtained from both the ambulatory cards
and separate ‘‘death registers’’ both held in each district.
Death data were subsequently veriﬁed by the Statistics
Division of the Ministry of Health for Karakalpakstan.
Patients were classiﬁed as lost to observation if there was
no subsequent DOTS registration and if no updated
ambulatory card was available, or if health care workers
reported that the patient had left Karakalpakstan.
Laboratory Methods
Sputum microscopy analysis was conducted routinely
through a network of DOTS TB laboratories utilizing the
Ziehl-Nielsen technique, following recommendations from
WHO/IUATLD [14,16]. Quality assurance was based on the
blinded rechecking of randomly selected sputum smears and
was within acceptable limits throughout the period included
in this study.
DST and DNA ﬁngerprinting (spoligotyping) was con-
ducted on M. tuberculosis strains obtained from patients at
initial diagnosis, but not at rediagnosis during the study
period. Cultures were obtained from sputum samples sent
directly from Karakalpakstan to the supranational reference
laboratory in Borstel, Germany and subsequently tested
against the ﬁve ﬁrst-line drugs used in the DOTS program.
Primary isolation and culture of mycobacterial isolates were
performed as described elsewhere [17]. DST was performed
on Lo ¨wenstein-Jensen media by the proportion method. If
growth was insufﬁcient, DST was conducted using the
modiﬁed proportion method on a BACTEC 460TB (Becton
Dickinson Microbiology Systems, Cockeysville, Maryland,
United States). Extraction of genomic DNA was performed
according to a standardized protocol [18]. All isolates were
analyzed by the spoligotyping technique to identify Beijing
genotype isolates [19].
Statistical Analysis
Treatment outcomes for different categories of patients
were compared using Pearson’s Chi
2 test, with p , 0.05
considered formally signiﬁcant. Recurrent TB after successful
treatment was assessed by survival curves, calculated using the
life table method with the Wilcoxon (Gehan) method used to
compare curves. Multivariate models of survival were based
on Cox’s proportional hazard model, with the Grambsch-
Therneau test of the proportional hazards assumption.
Factors entered into models included: treatment success,
categories of drug resistance, previous TB treatment, sex,
infection with M. tuberculosis Beijing strain, and rural versus
city residence. Interaction terms were introduced when
suggested by stratiﬁed analyses or where the investigators
believed they were plausible. Final models were generated
using a backward stepwise procedure: variables were removed
depending on the likelihood ratio test and after considering
changes to other estimates. Weibull regression was used to
test for changing hazard over time. Multivariate analysis of
factors predicting unsuccessful DOTS treatment used relied
on logistic regression with a similar variable selection
procedure and the same factors listed above. Analyses were
performed with either Epi-Info software (version 6.04d,
Centers for Disease Control, Atlanta, Georgia, United States)
or Stata (release 7; Stata Statistical Software, College Station,
Texas, United States).
Results
Study Sample
Valid observational data was obtained up to 30 September
2003 for 197 (92%) of the 213 patients included in the drug
resistance survey [13]. This was a median of 22 mo after
diagnosis (range 19–27). Patients were more often male
(64%), the mean age was 35 y (range 13–70), 40% lived in
rural districts, and 50% of patients reported previous TB
treatment of more than 1 mo duration.
DOTS Treatment Outcomes
DOTS end-of-treatment outcomes were similar to that seen
in Karakalpakstan as a whole; 74% (73/99) of new and 46%
(45/98) of previously treated cases were successfully treated
(Chi
2 ¼ 15.9; p , 0.0001) (Table 1). Overall, 29% of
successfully treated patients did not have sputum smear
conﬁrmation of cure at the end of treatment, and were
therefore classiﬁed as treatment completed. Patients provid-
ing saliva samples instead of sputum were also classiﬁed as
treatment completed.
Among the 66 new patients infected with pansusceptible or
monoresistant strains, 55 (83%) were classiﬁed as successfully
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43% (6/14) treatment success for new and only 24% (10/41)
for those previously treated. Patients infected with M.
tuberculosis strains resistant to more than one drug, but not
both isoniazid and rifampicin (deﬁned here as polyresistance)
had intermediate treatment success (63% among new, and
74% among previously treated).
Mortality
Mortality at the time of assessment was high, with 48 (24%)
of the 197 patients dead at the time of follow-up. This equates
to 15% of patients dying per year after diagnosis, ranging
from 2% among new pansusceptible cases to 69% in the small
number of new, MDR TB cases. Of the 33 patients who
defaulted from treatment, 12 (36%) had died at the time of
follow-up. Similarly, 11 (41%) of the 27 patients deﬁned as
treatment failures had died.
Overall, 96% of these deaths were recorded as being caused
by TB, with many deaths occurring within TB hospitals,
although cause of death was not veriﬁed by autopsy.
Recurrent TB
Among the 118 patients who were successfully treated, 42
(36%) were rediagnosed with active TB during the observa-
tion period, with 52% of these rediagnoses sputum smear
positive (Table 2). Patients classiﬁed as treatment completed
had signiﬁcantly higher smear-positive recurrence than those
classiﬁed as cured (Chi
2 ¼ 5.9; p ¼ 0.02), but no difference in
overall recurrence (Chi
2 ¼ 2.7; p ¼ 0.1). Among successfully
treated cases, TB recurrence (both smear-positive and over-
all) increased signiﬁcantly with increasing drug resistance
(Chi
2 ¼ 6.0; p ¼ 0.01). Interestingly, there were no signiﬁcant
differences in TB recurrence between new and previously
treated cases who were successfully treated (Table 2).
Many patients diagnosed with recurrent TB were subse-
quently reported to have died. Using the life table method, by
18 mo post-treatment only 65% of successfully treated
patients were still alive and had not been rediagnosed with
active TB (Figure 1). The rate of rediagnosis and/or death
appeared to increase signiﬁcantly across the observation
period (p ¼ 0.02), equating to a 1.3-fold increased hazard
(95% conﬁdence interval [CI], 1.04 to 1.76) at 12 mo
compared to 6 mo. When stratiﬁed by drug resistance,
disease-free survival at 18 mo ranged from 93% among those
infected with pansusceptible M. tuberculosis strains to 56%
among those with MDR TB (Figure 2).
Among the subgroup of 43 new patients infected with
pansusceptible M. tuberculosis strains and successfully treated,
recurrence of active TB remained signiﬁcant. Four and six
patients were rediagnosed with smear-positive and -negative
disease, respectively, with two deaths. By 18 mo after
treatment, only 78% remained alive and undiagnosed using
the life table method of survival analysis (Figure 1).
Factors Associated with Mortality and Recurrent TB
With time to death after diagnosis as an outcome, patients
who were successfully treated displayed a signiﬁcantly differ-
ent survival curve compared to those with unsuccessful
treatment outcomes (treatment failure, default, or death).
Therefore, in order to determine factors contributing to
mortality, the data were stratiﬁed by treatment success. After
stratiﬁcation, infection with MDR M. tuberculosis was the only
signiﬁcant predictor of mortality (hazard ratio, 3.0; 95% CI,
1.6 to 5.4).
As DOTS treatment outcome is clearly an important
predictor of mortality, a logistic regression analysis was used
to predict unsuccessful treatment. On univariate analysis,
previous TB treatment, MDR TB, M. tuberculosis Beijing
genotype, and city residence were signiﬁcant predictors.
However, in the multivariate model, Beijing genotype was no
longer signiﬁcant. The three factors predicting unsuccessful
treatment were: MDR TB (odds ratio, 5.6; 95% CI, 2.6 to 11.8),
previous treatment (2.2; 95% CI, 1.1 to 4.3), and city residence
(3.1; 95% CI, 1.6 to 6.2).
A separate model examined time from successful treatment
to death and/or rediagnosis among the 118 patients who were
successfully treated. On univariate analysis, polyresistance
and MDR TB were signiﬁcant. In the multivariate model, both
polyresistance and MDR TB remained signiﬁcant. Female sex
was a risk factor when combined with city residence
(interaction p ¼ 0.003), although neither of these factors was
separately associated with the outcome. Hazard ratios were:
polyresistance (3.1; 95% CI, 1.5 to 6.3), MDR TB (2.7; 95% CI,
1.3 to 5.9) and females in the city (2.9; 95% CI, 1.5 to 5.5).
When only mortality after successful treatment was assessed,
there was no signiﬁcant effect for city women.
Table 1. DOTS End-of-Treatment Outcomes by Categories of Drug Resistance in Terms of Previous TB Treatment
Treatment Susceptibility Cases (n) Cured Treatment
Complete
Treatment
Successful
b
Died Treatment
Failed
Defaulted
New cases Pansusceptible 53 32 11 43 (81%) 0 4 6
Monoresistant
a 13 9 3 12 (92%) 0 0 1
Polyresistant (not MDR) 19 7 5 12 (63%) 0 6 1
MDR TB 14 5 1 6 (43%) 6 2 0
Total 99 53 20 73 (74%) 6 12 8
Previously treated cases Pansusceptible 20 10 1 11 (55%) 0 4 5
Monoresistant
a 18 7 3 10 (56%) 1 2 5
Polyresistant (not MDR) 19 7 7 14 (74%) 2 1 2
MDR TB 41 7 3 24% 10 8 13
Total 98 31 14 46% 13 15 25
aNo patients were monoresistant to rifampicin.
bSuccessful treatment includes both cured and treatment completed cases.
DOI: 10.1371/journal.pmed.0030384.t001
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This study has demonstrated extremely high mortality and
high rates of disease recurrence after ‘‘successful’’ treatment
among TB patients treated with standardized short-course
chemotherapy under a routine DOTS program. Despite the
lack of data differentiating relapse from reinfection, high
recurrence in such settings of drug resistance suggests that
DOTS programs will have limited impact in terms of
reducing TB incidence. Overall, 15% of patients died per
year after diagnosis, and 36% of successfully treated patients
were rediagnosed with active TB. These poor post-treatment
outcomes are not hinted at by the end-of-treatment outcomes
for these patients, as commonly reported for DOTS pro-
grams. The 74% treatment success rate for newly diagnosed
patients is comparable to that achieved in many of the high
TB-burden countries deﬁned by WHO [2].
Infection with MDR TB had a direct impact on mortality
and, along with previous TB treatment and residence in the
city, contributed to poor end-of-treatment outcomes in the
DOTS program. Both MDR TB and drug polyresistance
contributed to high rates of recurrence and mortality after
successful treatment. Among those infected with MDR M.
tuberculosis, the rate of recurrent disease after successful
treatment was 63%, with the majority positive by sputum
smear. This rate is higher than the 28% recurrence reported
among 18 patients in Russia, where the median duration of
follow-up was only 6.5 mo [8]. Importantly, disease recurrence
in Karakalpakstan was also substantial among those infected
with polyresistant M. tuberculosis; 50% were rediagnosed after
successful treatment.
Control of TB, and especially the disease caused by drug-
resistant M. tuberculosis strains, seems unlikely in the face of
these results. This conclusion is in contrast to a recent study
from southern Mexico, in which a standard DOTS program
was shown to reduce incidence of both drug-susceptible and
drug-resistant TB [20]. However, this setting in southern
Mexico did not have a high TB incidence prior to the
implementation of DOTS (42/100,000/year) and reports a 3%
MDR TB level among new cases; these indices are consid-
erably lower than most of the high TB-burden and high drug-
resistance settings, including Karakalpakstan [2,21]. Addi-
tionally, it is likely that the patterns of M. tuberculosis drug
resistance seen in Mexico are less complicated than those in
Uzbekistan.
Although drug resistance is an important contributor to
poor long-term outcomes in this context, other factors may
be present; among new patients infected with pansusceptible
or monoresistant M. tuberculosis strains, treatment success was
83%, close to the WHO target of 85% [3]. But subsequently,
25% of these people were diagnosed with active TB again in
the 18 mo after ﬁnishing treatment, with 36% of these
recurrences sputum smear-positive. This result would suggest
that the long term ‘‘cure’’ rate is substantially less than the
83% reported at the end of treatment.
A central question arising from these data is whether these
recurrences of disease were caused by true relapses or by
reinfection with new strains of M. tuberculosis. If relapse is
common, it suggests that patients who are declared to be
‘‘successfully treated’’ in the DOTS program are not actually
cured. Such treatment failure could result from inadequate
treatment regimens, which in turn could arise through drug
resistance, poor adherence to treatment, poor drug quality,
or treatment regimens inadequate for this population,
independent of drug resistance. Alternatively, reinfection
could be an important contributor to an apparently high
Table 2. Recurrent TB by Drug Susceptibility among Successfully Treated Patients (n¼118), Stratified by Previous TB Treatment and by
Cure and Treatment Completion
Treatment Susceptibility Total
Cases
Total
Recurrent TB
(% of Total Cases)
Smear-Positive
Recurrent TB Cases
(% of Total Recurrent)
Smear-Negative
Recurrent TB Cases
(% of Total Recurrent)
Cured cases Pansusceptible 42 10 (24%) 3 (30%) 7 (70%)
Monoresistant 16 4 (25%) 1 (33%) 3 (67%)
Polyresistant 14 5 (36%) 2 (40%) 3 (60%)
MDR TB 12 7 (58%) 5 (71%) 2 (29%)
All cured 84 26 (31%) 11 (42%) 15 (58%)
Treatment completed cases Pansusceptible 12 3 (25%) 2 (66%) 1 (33%)
Monoresistant 6 2 (33%) 1 (50%) 1 (50%)
Polyresistant 12 8 (67%) 5 (63%) 3 (37%)
MDR TB 4 3 (75%) 3 (100%) 0
All completed 34 16 (47%) 11 (69%) 5 (31%)
New cases Pansusceptible 43 10 (23%) 4 (40%) 6 (60%)
Monoresistant 12 4 (33%) 1 (25%) 3 (75%)
Polyresistant 12 7 (58%) 4 (57%) 3 (43%)
MDR TB 6 4 (67%) 4 (100%) 0
All new 73 25 (34%) 13 (52%) 12 (48%)
Previously treated cases Pansusceptible 11 3 (27%) 1 (50%) 2 (50%)
Monoresistant 10 2 (20%) 1 (50%) 1 (50%)
Polyresistant 14 6 (43%) 3 (50%) 3 (50%)
MDR TB 10 6 (60%) 4 (67%) 2 (33%)
All previously treated 45 17 (38%) 9 (53%) 8 (47%)
All successfully treated 118 42 (36%) 22 (52%) 20 (48%)
DOI: 10.1371/journal.pmed.0030384.t002
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caused by a high prevalence of infectious TB in the
community, low levels of immunity among individuals
completing TB treatment, HIV infection, or speciﬁc charac-
teristics of circulating M. tuberculosis strains. Without DNA
ﬁngerprinting of strains at rediagnosis, it is not possible to
determine the relative contributions of relapse and reinfec-
tion in this study. The data suggest, however, that the rate of
TB recurrence (and death) is, at least, not decreasing
throughout the observation period; since relapse is thought
to predominate in the ﬁrst 6 mo after treatment completion
[22], this suggests that both mechanisms may be involved.
In Karakalpakstan, most patients are hospitalized for the
intensive phase of treatment, maximizing adherence to
treatment. This practice was conﬁrmed in a survey conducted
in 2002 [23]. Randomly selected patients on intensive and
continuation phases of treatment were interviewed to
determine treatment observation and adherence. While both
adherence and observation were considered adequate during
the intensive phase (more than 80% of patients were
observed for more than 80% of doses), observation declined
in the continuation phase, with only 41% of patients
observed taking more than 80% of doses. However, only
12% of patients reported missing more than 20% of doses in
the continuation phase, and many of these patients went on
to be recorded as default from treatment. Although no drug
resistance data were available, among 11 patients from this
survey known to have had more than 80% of doses observed,
four patients were subsequently rediagnosed with sputum
smear-positive TB. Therefore, it seems that poor adherence
may not wholly explain the high disease recurrence rates seen
here. Rates of default from treatment are higher in the main
city in Karakalpakstan, however, resulting in the ﬁnding that
city residence contributes signiﬁcantly to unsuccessful treat-
ment. This is most likely the result of overcrowding in TB
facilities and poorer motivation among health care workers.
Such ﬁndings demonstrate that despite signiﬁcant inputs,
there remain problems in program quality that manifest in
poor observation of treatment.
Another possible explanation for high relapse may be poor
drug quality. However, the antituberculosis drugs used in the
Karakalpakstan DOTS program were supplied by MSF and
sourced through the International Dispensary Association up
to 2002. Subsequently, drugs were and are supplied to the
Ministry of Health in Uzbekistan through the German
Development Bank. Although this problem is possible,
because of its sources drug quality seems unlikely to be a
major explanatory factor.
If relapse is signiﬁcant and cannot be completely attributed
to drug resistance, poor adherence, or poor drug quality, we
are led to question the adequacy of the drug regimes
themselves under routine program conditions. To date there
have been only two observational studies assessing post-
treatment outcomes from functioning DOTS programs (using
DOTS-recommended short-course chemotherapy regimens);
both of these studies in India demonstrate an 11% rate of
smear- or culture-positive disease recurrence [24,25]. It is
therefore possible that the recommended treatment regimens
are inadequate in some populations, given the realities of
programmatic conditions.
Studies utilizing DNA ﬁngerprinting of M. tuberculosis
strains have shown that reinfection contributes more
substantially to recurrent TB than previously thought [26],
with between 12% and 77% of cases attributable to
reinfection [27–31]. It is therefore plausible that in the
high-prevalence region of Karakalpakstan, with many in-
fected persons harboring drug-resistant strains, reinfection
may contribute substantially to TB recurrence.
The high rates of mortality and recurrent TB seen here
would, in many settings, suggest a high prevalence of HIV
infection. HIV prevalence is reported to be increasing rapidly
in the Central Asian republics [32]. However, in Uzbekistan,
HIV seems, at present, to be conﬁned to illicit users of
injected drugs, particularly in the larger cities of Tashkent
and Samarkand. In Karakalpakstan, ofﬁcially, there were four
cases of HIV infection up to 2004, and these were all reported
in 2003. Despite the lack of widespread, adequate HIV testing,
the data suggest that HIV has not yet affected the TB
epidemic in Karakalpakstan.
Study Limitations
As this was an observational study of a functioning DOTS
program, there are a number of limitations to the data
Figure 2. Effect of Drug Resistance on Continued Treatment Success
over Time
Shown are percentages of successfully treated patients remaining alive
and undiagnosed over time (life table method) by categories of drug
resistance
DOI: 10.1371/journal.pmed.0030384.g002
Figure 1. Continued Treatment Success over Time for New Pansuscep-
tible Cases Compared to the Complete Study Sample
Shown are cumulative percentages of successfully treated patients
remaining alive and undiagnosed over time (life table method) for the
complete study sample (n ¼ 118) and for the subgroup of new,
pansusceptible cases (n ¼ 43). At 12 mo post-treatment 84% of new,
pansusceptible cases were still alive and free of TB compared to 72% in
the complete sample.
DOI: 10.1371/journal.pmed.0030384.g001
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TB Recurrence after DOTS Treatmentavailable for analysis. Principal among these limitations is the
lack of adequate data on treatment adherence. Although
observation of doses is routinely recorded, the survey
mentioned above found that these data did not accurately
reﬂect the true situation; therefore it was not used to assess
treatment adherence in the current analysis. It is therefore
not possible to determine the exact contribution to disease
recurrence and mortality due to poor adherence in this study.
The relatively high proportion of successfully treated
patients classiﬁed as ‘‘treatment completed’’ may also be
considered a study limitation. The lack of a valid sputum
smear result at the end of treatment potentially suggests poor
adherence to treatment and a failure to complete the full
treatment regimen. However, in the majority of such cases,
the lack of a valid result was due to samples being recorded as
‘‘saliva’’ rather than sputum and therefore not analyzed. This
suggests that sputum collection at the end of treatment is not
adequately supervised or that patients could not actually
produce sputum, not that patients failed to ﬁnish treatment.
In contrast, the signiﬁcantly higher proportion of smear-
positive recurrences among the treatment-completed cases
does suggest poorer adherence and emphasizes the need to
obtain bacteriologically veriﬁed cure at the end of treatment.
The use of a recorded rediagnosis of TB was considered to
be valid in this study due to the completeness of record-
keeping and patient follow-up, carried forward from the
previous treatment strategy. However, the lower rate of
rediagnosis, but not mortality, among rural women, suggests
that access to rediagnosis may be less than ideal, at least for
some patients. This effect would result in an underestimated
rate of recurrent TB. Conversely, since only sputum smear
microscopy was used for rediagnosis, sputum smear-negative
rediagnoses may be doubtful. However, a treatment commit-
tee assessed smear-negative rediagnoses, and only those
started on the DOTS retreatment regime were included in
this analysis. Additionally, the proportion of smear-positive
rediagnoses is similar to that seen among new patients at
diagnosis in the DOTS program in Karakalpakstan, suggest-
ing that overdiagnosis is not signiﬁcant among patients with
recurrent disease.
Conclusion
This study has shown very poor post-treatment patient
outcomes for individuals diagnosed and treated for active TB
in a relatively well-functioning DOTS program. These data
suggest that, at least in this setting, and potentially in other
settings with similar drug resistance proﬁles, DOTS programs
are not sufﬁcient to cure a sufﬁcient number of individuals or
for TB control. The expansion of DOTS-Plus programs for
the speciﬁc treatment of drug-resistant TB is therefore
urgently needed, particularly in resource-poor settings.
Further studies differentiating relapse and reinfection are
also required to formulate appropriate interventions. Addi-
tionally this study highlights the need for similar investiga-
tions into long-term outcomes from functioning DOTS
programs in other settings.
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Editors’ Summary
Background. Throughout history, tuberculosis (TB) has been a leading
infectious cause of death—it kills about 2 million people every year. Until
the 1940s, there was no effective treatment for TB, a chronic bacterial
infection, usually of the lungs. Then, antibiotics active against the
bacteria that cause TB—Mycobacterium tuberculosis—were introduced,
and its incidence (the annual number of new cases) declined rapidly,
particularly in developed countries. However, in the 1980s, there was a
resurgence of TB, much of it driven by the HIV/AIDS epidemic—people
with damaged immune systems are very susceptible to TB—and the
emergence of drug-resistant M. tuberculosis. In 1995, the World Health
Organization instigated what it called ‘‘DOTS,’’ an international strategy
for global TB control. Central to DOTS is directly observed standardized
short-course drug treatment. To prevent relapse and the emergence of
drug-resistant bacteria, TB patients have to take antibiotics regularly for
six months, even if they feel better sooner. The DOTS approach ensures
that they do this by having trained observers watch them swallow their
medications.
Why Was This Study Done? DOTS aims to detect 70% of new cases of
sputum smear-positive TB (sputum is mucus coughed up from the lungs)
and to treat 85% of these patients successfully. Both a cure—a negative
smear at the end of treatment—and completion of treatment are
recorded as ‘‘treatment successes.’’ There is no requirement in DOTS to
check for TB recurrence, and few studies have investigated the long-term
outcomes of treatment, particularly in areas with a high TB burden or
where there is a problem with multidrug-resistant TB. Such data are
needed to indicate whether DOTS can deliver global TB control. In this
study, the researchers asked how often TB recurred in patients treated in
a DOTS program in Karakalpakstan, Uzbekistan, an area with one of the
highest incidences of multidrug-resistant TB.
What Did the Researchers Do and Find? The researchers identified
about 200 sputum smear-positive TB patients who were treated
consecutively in the Karakalpakstan DOTS program in 2001–2002. For
most of the patients, follow-up data were available for an average of 22
months, a legacy of the pre-DOTS TB treatment system in Uzbekistan.
The researchers found that, although three-quarters of new cases were
‘‘successfully’’ treated (i.e., close to the DOTS goal), a third of these
‘‘successes’’ were later re-diagnosed with TB. Recurrence of TB was
particularly common among patients whose initial disease was multidrug
resistant. Previous TB treatment was also associated with an increased
risk of disease recurrence. Overall, nearly a quarter of the study patients
died from TB during the follow-up period. Again, patients initially
infected with multidrug-resistant TB fared particularly badly. Finally, only
65% of successfully treated patients were still alive and had not been re-
diagnosed with TB 18 months after completion of their treatment.
What Do These Findings Mean? These high rates of disease recurrence
and mortality suggest that DOTS might not be sufficient to control TB in
areas like Karakalpakstan where the disease burden is high and
multidrug-resistant infections are common. These poor long-term
outcomes, note the researchers, are not hinted at by the end-of-
treatment outcomes reported by the DOTS program. Limitations in the
present study mean, however, that further studies are needed before
these findings can be extrapolated to other settings. For example, the
study used historical data so the researchers could not determine
whether inadequate adherence to the DOTS program had contributed to
the poor long-term outcome or whether disease recurrence was due to a
relapse of the initial infection (which might indicate poor treatment
adherence) or a new infection. Nevertheless, the current results warn
against relying on end-of-treatment outcomes to judge the potential
effectiveness of DOTS in controlling TB, and suggest that the expansion
of DOTS-Plus, a supplement to DOTS for use where multidrug resistant
TB is common, should be made a priority.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030384.
  US National Institute of Allergy and Infectious Diseases, patient fact
sheet on tuberculosis
  US Centers for Disease Control and Prevention, information for patients
and professionals on tuberculosis
  MedlinePlusencyclopedia entry on tuberculosis
  NHS Direct Online, patient information on tuberculosis from the UK
National Health Service
  World Health Organization information on the global elimination of
tuberculosis, including details of DOTS and DOTS-Plus
  Mede ´cin sans Frontie `res; information on TB and other health issues in
Karakalpakstan
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